Turn Therapeutics CFO Acquires Additional TTRX Shares in Small Purchase
Turn Therapeutics Inc.
Subscribe to track TTRX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Turn Therapeutics CFO Acquires TTRX Shares
Company: Turn Therapeutics Inc. (TTRX) Form: 4 | Filed: 2025-11-17 Significance: Low
Insider: Chaudhary Zuraiz Title: Interim CFO, VP of Finance & CAO | Relationship: Officer
Transaction: • Type: Buy • Shares: 2,500 • Price: $3.62 (avg) • Value: $9,050 • Owned After: 7,550
Key Insight: A key financial executive made a small open-market purchase, a positive signal, but the transaction's value is negligible relative to the company's market cap.
Market Context: The purchase represents less than 0.01% of the company's $110 million market capitalization, indicating a minor addition to the insider's position.
Comprehensive Analysis
SEC Filing Analysis: Turn Therapeutics Inc. (TTRX)
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Interim Chief Financial Officer of Turn Therapeutics made a small open-market purchase of common stock valued at approximately $9,050.
- Market Impact: Neutral. The transaction size is too small to be considered market-moving.
Company Information
| Field | Value |
|---|---|
| Company | Turn Therapeutics Inc. |
| Ticker Symbol | TTRX |
| CIK | 0002023016 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Chaudhary Zuraiz |
| CIK | 0002086494 |
| Title/Position | Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer. |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-17 |
| Transaction Code | P (Open Market Purchase) |
| Security Type | Common Stock |
| Shares Involved | 2,500 |
| Price Per Share | $3.62 |
| Total Value | $9,050 |
| Shares Owned After | 7,550 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $9,050 |
| % of Market Cap | 0.0082% |
| Shares Transacted | 2,500 |
| % of Shares Outstanding | Not Available |
| Post-Transaction Ownership | 7,550 shares |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The transaction value of $9,050 is negligible when compared to Turn Therapeutics' market capitalization of $110 million. It represents a very small fraction of the company's total value.
- Ownership Concentration: Without data on shares outstanding, the insider's total ownership percentage cannot be calculated. However, the purchase itself is minor.
- Transaction Significance: The purchase is considered to have low significance. While insider buys are generally positive indicators, the extremely small size of this transaction relative to the company's market cap diminishes its signaling power.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: An open-market purchase by a CFO is a positive sign of confidence. However, the total value of $9,050 is insignificant for a company with a $110 million market cap, making any market reaction unlikely.
Volume & Sentiment
- Expected Volume Impact: Minimal. The transaction is too small to impact trading volume.
- Sentiment Indicator: Neutral. The positive nature of the buy is offset by its immaterial size.
Additional Context
Transaction Notes
- The reported price of $3.62 is a weighted average. The shares were purchased in multiple transactions at prices ranging from $3.50 to $3.69.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
